ABL1 and Parkinson disease: Parkinson disease (PD) is the second most common neurodegenerative disease, affecting 1% of the population older than 65 years.1 Slowing PD progression remains a major unmet need.2 Nilotinib, an approved therapy for chronic myeloid leukemia, works predominantly via BCR-Abelson tyrosine kinase (c-Abl) inhibition.